Advancing Collective Priorities: A Canadian Carer Strategy

The Canadian Cancer Action Network, in partnership with Carers Canada and the Canadian Home Care Association, is pleased to publically launch the 2017 report, Advancing Collective Priorities: A Canadian Carer Strategy today. Over 8 million carers (also referred to as family caregivers) impact the lives of Canadians every day. Providing care and support to loved

New Drug Therapy – COTELLIC ZELBORAF Effective June 1, 2017

New criteria for the following products have been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) Benefit List effective June 1, 2017. Special Authorization New Addition The following was reviewed by the pan Canadian Oncology Drug Review (pCODR) recommended for coverage with criteria: COTELLIC (Cobimetinib) 20mg DIN 02452340 In combination with vemurafenib, for

Ontario Cancer Research Ethics Board Call for Community Members

A research ethics board (REB) is a body of researchers, community members and others that is established to review the ethical acceptability of research involving humans. Working within a defined regulatory and ethical framework, the REB’s role is to safeguard the rights and welfare of the individuals who volunteer to participate in research. The composition

Provincial/Territorial Premiers Prescription for Health Encouraging; Patient groups look forward to working with them to achieve equitable access to treatments for all Canadians

EDMONTON, AB. – July 19th, 2017 – The provincial/territorial Premiers met today at the Council of the Federation in Edmonton, Alberta. Health was on the agenda. Patient groups, patients, caregivers and their supporters were in Edmonton to follow the outcome of the meeting. They wanted to ensure that the decisions made enhanced access to necessary

Cotellic (Cobimetinib) in Québec

COBIMETINIB: in association with vemurafenib, for first-line or second-line treatment following a failure with cytotoxic chemotherapy or with immunotherapy targeting the PD-1 or the CTLA-4, of an unresectable or metastatic melanoma with a BRAF V600 mutation, in persons whose ECOG performance status is 0 or 1. The initial authorization is for a maximum duration of